Serum anti-Mullerian hormone and homocysteine in premenopausal females with and without cardiovascular disease
Keywords:Anti-Mullerian hormone, Cardiovascular disease, Homocysteine, Pre-menopause
Background: The objective of this study is to assess the association of anti-Mullerian hormone (AMH) and homocysteine (Hcy) levels in premenopausal females with and without cardiovascular disease.
Methods: A case control study was conducted in premenopausal, menopausal and normal fertile females (n=30) with and without cardiovascular disease in a tertiary care hospital and research centre in central India. Fasting sample obtained was assessed for AMH and Hcy levels. Results were compared and data was analyzed.
Results: The levels of AMH and Hcy were significantly altered in premenopausal and menopausal females as compared to normal fertile females. Moreover, there was a weak correlation when intergroup comparison was made between the parameters in females with and without cardiovascular disease.
Conclusions: A prospective study with a larger sample size to assess levels of AMH need to be performed to provide insight in premenopausal females for the early detection cardiovascular disease.
Kim ES, Menon V. Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol. 2009;29:279-83.
Yang XP, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20(2): 133-8.
E Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for overian aging. Fertil Steril. 2002;77:357-2.
Sirsikar M, Pinnelli V, Mohanty S, Jayashankar CA. Anti-Müllerian hormone in health and disease: a review. Int J Res Med Sci. 2016; 4(7):2514-20.
Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13(2):265-79.
Susan E, Haiying Chen, Thomas B Clarkson. Jay R Kaplan. Premenopausal antimüllerian hormone concentration is associated with subsequent atherosclerosis. Menopause. 2012;19(12): 1353-9.
Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutrit J. 2015;14(1):6.
Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, et al. Hyperhomocysteinemia decreases circulating HDL by inhibiting apoA-I protein synthesis and enhancing HDL-C clearance. Circ Res. 2006;99:598-606.
Zhao Z, Wang H, Jessup JA, Lindsey SH, Chappell MC, Groban L. Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2014;306: H628-40.
Crandall CJ, Barrett-Connor E. Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: a systematic review. Endocrinol Metab Clin North Am. 2013;42:227-3.
Lowery JW, de Caestecker MP. BMP signaling in vascular development and disease. Cytokine Growth Factor Reviews. 2010;21(4):287-98.
Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-Mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab. 2012;97(5):1673-80.
Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, et al. Serum antimüllerian hormone in healthy premenopausal women. Fertil Steril. 2011;95(8):2718-21.
Zhang C, Yong C, Adachi MT, Oshiro S, Aso T, Kaufman RJ. Homocysteine induces programmed cell death in human vascular endothelial cells through the activation of the unfolded protein response. J Biol Chem. 2001;276:35867-4.
Gambacciani M, Mannella P. Homocysteine, menopause and cardiovascular disease. Menopause Int. 2007;13(1):23-6.
Hak AE, Polderman KH, Westendorp IC, Jakobs C, Hofman A, Witteman JC, et al. Increased plasma homocysteine after menopause. Atheroscler. 2000;149(1):163-8.
Wouters MG, Moorrees MT, van der Mooren MJ, Blom HJ, Boers GH, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest. 1995;25(11):801-5.
De Kat AC, Verschuren WM, Eijkemans MJ, Broekmans FJ, Van Der Schouw YT. Anti-Müllerian hormone trajectories are associated with cardiovascular disease in women clinical perspective: results from the Doetinchem cohort study. Circulat. 2017;135(6):556-65.